Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study.

In addition, patients who received RC48 as second-line therapy showed a trend toward an increased risk of disease progression, but this association did not reach statistical significance (p = 0.120) and should be interpreted cautiously, as the study was not designed or powered to formally compare treatment lines and larger cohorts will be required for validation.

also in 53,322 other papers

In the multivariable Cox regression model, BMI remained an independent protective factor (HR = 0.82, 95% CI, 0.70–0.96; p = 0.012), while second-line treatment continued to show a trend toward increased risk (HR = 2.03, 95% CI, 0.83–4.97; p = 0.120), although this did not reach statistical significance ( Table 2 ; Figure 2 ).

also in 111,027 other papers